News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Arana Therapeutics Announces Phase II Trials For Lead Compound ART621
December 4, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Tuesday, 4 December 2007 Sydney, Australia: Biotechnology company Arana Therapeutics Limited (ASX: AAH, AIM: AAHx) today announced plans for the next stages of clinical development for ART621 – its lead anti-TNF domain-based antibody.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Australia
MORE ON THIS TOPIC
Infectious disease
Gilead, GSK/ViiV, Merck Present New HIV PrEP Frontiers at IAS25
July 15, 2025
·
4 min read
·
Tristan Manalac
Obesity
Hengrui’s Dual GLP-1/GIP Elicits 17.7% Weight Loss in Phase III
July 15, 2025
·
2 min read
·
Dan Samorodnitsky
Drug Development
The Gap Between the Administration’s Pro-Innovation Words and Policy
July 14, 2025
·
6 min read
·
Lori Ellis
Cardiovascular disease
AstraZeneca’s Baxdrostat Pushes Blood Pressure Lower in Phase III Trial
July 14, 2025
·
1 min read
·
Dan Samorodnitsky
